

May 28, 2022

To  
The General Manager  
Department of Corporate Services  
**BSE Limited**  
P.J. Towers, Dalal Street,  
Mumbai-400001  
**Scrip Code – 543298**

To  
The Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No – C/1,  
G Block, BandraKurla Complex  
Bandra (East), Mumbai -400 051  
**Scrip Code - VINEETLAB**

Dear Sir/Ma'am,

**Sub: Outcome of Board Meeting held on Saturday, May 28, 2022**

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

The Board of Directors of the company in its meeting held today i.e., on May 28, 2022 has considered and approved the following:

1. The Annual Audited Financial Results of the company for the Fourth Quarter and the Financial Year ended on 31<sup>st</sup> March, 2022;
2. The Annual Audited Financial Statements for the financial year 2021-2022;
3. Independent Auditor's Report on Quarterly Standalone Financial Results and Year to Date.
4. Recommended Final Dividend at Re.1/- per equity share of Face Value of Rs.10 each for the financial year ended March 31, 2022.

The Board Meeting commenced at 04.00 PM and concluded at 08.00 PM

Kindly take this information on records.

Regards,

ForVineet Laboratories Limited



Gaddam Venkata Ramana  
Managing Director  
DIN: 00031873





**Independent Auditor's Report on Quarterly Standalone Financial Results and Year to Date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015**

**To the Board of Directors of VINEET LABORATORIES LIMITED**

**Report on the Audit of Standalone Financial Results**

**Opinion**

We have audited the accompanying standalone annual financial results of **VINEET LABORATORIES LIMITED** hereinafter referred to as 'the Company' for the quarter and year ended March 31, 2022 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the company for the year ended March 31, 2022.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.





### Emphasis Matter

1. During the year 2020-21 M/s. Ortin Laboratories Ltd has demerged and Unit -II of M/s. Ortin Laboratories Ltd is merged with M/s. Vineet Laboratories Limited and the accounts of Unit -II of M/s. Ortin Laboratories Ltd considered in to the books of accounts of the company as per Order of the Hon'ble NCLT, Hyderabad Bench, dated 24.12.2020. Accordingly, the Accounts of Unit-II of M/s. Ortin Laboratories Ltd have been considered in the book of accounts of M/s. Vineet Laboratories Ltd for the financial year 2020-21 and financial year 2021-22.
2. During the year under review the company has received the notice from Addl Director, Director General of GST Intelligence, Visakhapatnam Zone u/s.74(5) of CGST Act 2017 with regard to availing of input tax credit of Rs.88,60,129/- on invoices without movement of goods of Rs.4,92,22,940/- from M/s. Raj Solvents Pvt Ltd during the years 2019-20 & 2020-21 relating to Unit II of M/s. Ortin Laboratories Ltd. During the year the Company accounted the liability on account of wrong availing of ITC of Rs.88,60,129/- and considered as expenditure for the year. On account of this the profit of the company was reduced by Rs.88,60,129/-.
3. During the year under review the company has received the notice from Addl Director, Director General of GST Intelligence, Visakhapatnam Zone u/s.74(5) of CGST Act 2017 with regard to availing of input tax credit of Rs.14,90,453/- on invoices without movement of goods of Rs.82,80,290/- from M/s. Raj Solvents Pvt Ltd during the year 2021-22. On account of the above transactions the profit of the company lower stated to the extent of Rs.97,70,743/-.
4. The company has received U/s.91 & 160 Cr.P.C.1973 on 22.03.2022 from Central Bureau of Investigation, Banking Securities & Fraud Branch, Bangalore on LC No.0192111LC0000981 for Rs.2,31,63,000/- dated 31.10.2011 with regard to discounting of the LC.
5. During the year under review, the company has made purchases to the extent of Rs.64,74,99,598/- from the related parties and sales to related parties of Rs.86,89,11,276/- and the same has been netted off in the party ledger accounts.
6. The company is in the business of manufactures of pharmaceutical intermediates and the inventories are considered as certified by the management.
7. Account receivables and payables are subject to confirmation from the respective parties and majority of the accounts receivable are long outstanding's.



- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.





## **Board of Directors' Responsibilities for the Standalone Financial Results**

This Statement have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss and other comprehensive income in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:




**Other Matters:**

The statement includes the results for the quarter ended March 31, 2022 being the balance figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matters.

For M M REDDY & CO.,  
Chartered Accountants  
Firm Registration No.010371S

  
M. Madhusudhana Reddy  
Partner  
Membership No.234165  
UDIN: 22213077AJUUF01272



Date: 28.05.2022  
Place: Hyderabad




**VINEET LABORATORIES LIMITED**  
**CIN:L24304TG2016PLC112888**

Registered Office : SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.


**Statement of Financial Position as at March 31, 2022**

	Particulars	Note No.	As at March 31, 2022 (₹)	As at March 31, 2021 (₹)
I	<b>ASSETS</b>			
1	<b>Non-current assets</b>			
	(a) Property, plant and equipment	2	2,138.41	1,966.53
	(b) Right to use assets		-	-
	(c) Capital work in progress		-	-
	(d) Investment properties		-	-
	(e) Good will		-	-
	(f) Other intangible Assets		-	-
	(g) Intangible Assets under Development		-	-
	(h) Biological Assets other than Bearer Plants		-	-
	(d) Financial assets		-	-
	(i) Investments	3	13.57	11.80
	(ii) Trade receivables	4	403.44	133.37
	(iii) Loans & Advances	5	487.73	100.24
	(vi) other Fiancial assets	6	-	-
	(e) Deferred Tax Asset (Net)	7	-	-
	(f) Other non-current asset	8	47.02	25.97
	<b>Total non-current assets (A)</b>		<b>3,090.17</b>	<b>2,237.92</b>
2	<b>Current assets</b>			
	(a) Inventories	9	4,353.98	3,968.57
	(a) Financial assets			
	(i) Investments	3	-	-
	(ii) Trade receivables	4	3,619.83	4,271.40
	(iii) Cash and cash equivalents	10	1,665.94	75.09
	(iv) Bank Balances other than (iii) above		145.75	135.08
	(v) Loans	5	-	-
	(iv) other financial assets	6	-	-
	(b) Current Tax Asset (Net)		-	-
	(c) Other current assets	11	487.40	186.10
	<b>Total current assets (B)</b>		<b>10,272.91</b>	<b>0.09</b>
	Non Current Assets Clasified as Held for Sale( C)	12	-	-
	<b>Total assets (A+B+C)</b>		<b>13,363.08</b>	<b>2,238.00</b>
II	<b>EQUITY AND LIABILITIES</b>			
1	<b>Equity</b>			
	(a) Equity share capital	13	921.90	921.90
	(b) Other equity	14	2399.92	1,739.60
	<b>Total equity (A)</b>		<b>3,321.82</b>	<b>2,661.50</b>
2	<b>Liabilities</b>			
(i)	<b>Non-current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings	15	172.19	346.56
	(ii) Trade Payables	16	72.05	70.05
	(iii) Other Financial Liabilities	17	-	-
	(b) Long term provisions	18	109.57	104.32
	(c) Deferred tax Liabilities(Net)	7	179.11	226.75
	(d) Other non Current Liabilities		-	-
	<b>Total non-current liabilities (B)</b>		<b>532.92</b>	<b>747.67</b>
(ii)	<b>Current liabilities</b>			
	(a) Financial liabilities			
	(i) Borrowings	15	2,479.17	900.73
	(ii) Trade payables	16	6,009.18	5,598.77
	(iii) Other financial liabilities	17	419.41	593.37
	(b) Short term provisions	18	318.33	124.07
	(c) Other current liabilities	19	282.65	248.05
	(d) Current Tax Laibilities (net)	7	-	-
	<b>Total current liabilities (C)</b>		<b>9,508.74</b>	<b>7,464.99</b>
	<b>Total liabilities (D+B+C)</b>		<b>10,041.66</b>	<b>8,212.65</b>
	<b>Total equity and liabilities (A+D)</b>		<b>13,363.08</b>	<b>10,874.15</b>

The notes are an integral part of the financial statemer




SCHEDULE III OF COMPANIES ACT, 2013						
PART II - AUDITED STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2022						
Name of the Company - VINEET LABORATORIES LIMITED						
CIN:L24304TG2016PLC112888						
Registered Office : SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.						
Profit and Loss Statement for the Quarter and Year ended 31ST MARCH, 2022						
(Rs. In Lakhs)						
Particulars	STANDALONE FINANCIALS					
	Quarter Ended			Year Ended		
	31-03-2022 Audited	31-12-2021 Unaudited	31-03-2021 Audited	31-03-2022 Audited	31-03-2021 Audited	
I Revenue From Operations	5558.61	3,836.47	24,347.89	19117.23	24347.89	
II Other Income	10.78	(0.57)	38.60	28.51	38.60	
III Total Revenue (I+II)	5569.39	3835.90	24386.49	19145.74	24386.49	
IV Expenses						
Cost of Materials Consumed	4328.93	3430.22	19275.52	15139.89	19275.52	
Purchases of Stock-in-trade	-	-	-	-	-	
Changes in inventories of finished goods Work-in-progress and Stock-in-trade	-398.44	(485.29)	535.79	-585.25	535.79	
Employee benefits expense	101.98	110.25	557.06	490.94	557.06	
Finance Costs	78.53	35.18	266.65	216.84	266.65	
Depreciation and Amortisation expense	51.96	49.96	180.67	201.57	180.67	
Other Expenses	919.82	517.67	3164.96	2747.22	3164.96	
Total Expenses	5082.78	3658.00	23980.65	18211.19	23980.65	
V Profit/ (Loss) before Exceptional Items and tax (III-IV)	486.62	177.90	405.84	934.55	405.83	
VI Exceptional Items	-	-	-	-	-	
VII Profit / (Loss) from before tax (V-VI)	486.62	177.90	405.84	934.55	405.83	
VIII Tax Expense:						
Current Tax	206.34	41.77	127.87	318.33	127.87	
Deferred Tax	-47.63	-	99.93	-47.63	99.93	
IX Profit/ (Loss) for the period from continuing operations (VII-VIII)	327.91	136.12	178.04	663.86	178.03	
X Profit/ (Loss) from discontinuing operations	-	-	-	-	-	
XI Tax Expense of discontinuing operations	-	-	-	-	-	
XII Profit/ (Loss) from discontinuing operations after tax	-	-	-	-	-	
XIII Profit/(loss) for the Period (IX+XII)	327.91	136.12	178.04	663.86	178.03	
XIV Other Comprehensive Income						
A. (i) Items that will not be recycled to profit or loss	-	-	-	-	-	
(a) Others (gratuity and leave encashment excess provision reversal)	-	-	22.61	-	22.61	
(ii) Income tax relating to items that will not be reclassified to profit or loss	3.54	-	-	3.54	-	
B. (i) Items that may be reclassified to profit or loss	-	-	-	-	-	
(ii) Income tax on items that may be reclassified to profit or loss	-	-	-	-	-	
Total Comprehensive Income	3.54	-	22.61	3.54	22.61	
XV Total Comprehensive Income for the period (XIII+XIV)	334.98	136.12	200.65	660.32	200.64	
XVI Earnings Per Equity Share of face value of Rs.10/- each (for Continuing operations):						
1) Basic	3.63	1.48	2.18	7.16	2.18	
2) Diluted	3.63	1.48	2.18	7.16	2.18	
XVII Earnings Per Equity Share of face value of Rs.10/- each (for Discontinuing operations):						
1) Basic	0.00	0.00	0.00	0.00	0.00	
2) Diluted	0.00	0.00	0.00	0.00	0.00	
XVIII Earnings Per Equity Share of face value of Rs.10/- each (for Continued and Discontinuing operations):						
1) Basic	3.63	1.48	2.18	7.16	2.18	
2) Diluted	3.63	1.48	2.18	7.16	2.18	
XIX Paid-up equity share capital (Face Value of Rs. 10/- per share)	921.90	921.90	921.90	921.90	921.90	






VINEET LABORATORIES LIMITED		
CIN:L24304TG2016PLC112888		
Registered Office: SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.		
CASH FLOW STATEMENT FOR THE YEAR ENDED 31st March, 2022		
Particulars	31.03.2022	31.03.2021
	(₹)	(₹)
<b>A. CASH FROM OPERATING ACTIVITIES</b>		
(Loss)/Profit before tax and extraordinary items	934.55	405.83
<b>Adjustment for:</b>		
Income tax expense recognised in profit or loss	(318.33)	127.87
Finance costs recognised in profit or loss	216.84	266.65
Interest income recognised in profit or loss	(16.24)	(4.62)
Gain on disposal of property, plant and equipment	-	-
Gain on disposal of a subsidiary	-	-
Gain on disposal of interest in former associate	-	-
Net (gain)/loss recorded in profit or loss on financial liabilities designated as at fair value through profit or loss	-	-
Net (gain)/loss arising on financial assets mandatorily measured at fair value through profit or loss	-	-
Net loss/(gain) arising held for trading financial liabilities	-	-
Hedge ineffectiveness on cash flow hedges	-	-
Net (gain)/loss on disposal of available-for-sale financial assets	-	-
Impairment loss recognised on trade receivables	-	-
Reversal of impairment loss on trade receivables	-	-
Depreciation and amortisation of non-current assets	201.57	180.67
Impairment of non-current assets	-	-
Net foreign exchange (gain)/loss	-	-
Expense recognised in respect of equity-settled share-based payments	-	-
Expense recognised in respect of shares issued in exchange for goods/services	-	-
Amortisation of financial guarantee contracts	-	-
Other Non cash Adjustment	(3.54)	-
<b>Operating Profit before Working Capital Changes</b>	<b>1,014.85</b>	<b>976.41</b>
<b>Movement for Working Capital:</b>		
(Increase)/ decrease in trade and other receivables	4,271.40	(4,271.40)
(Increase)/decrease in amounts due from customers under construction contracts		
(Increase)/decrease in inventories	(385.41)	(3,968.57)
(Increase)/decrease in other assets	(301.30)	(146.55)
Increase/ (Decrease) in trade and other payables	410.42	5,598.77
Increase/(decrease) in amounts due to customers under construction contracts		
Increase/(decrease) in provisions	194.26	124.07
(Decrease)/increase in deferred revenue		
(Decrease)/increase in other liabilities	(139.76)	827.90
Changes in non current assets and liabilities		
Decrease/(Increase) in loans & advances		
Decrease/(Increase) in Long Term Provisions		
Decrease/(Increase) in Other non Current Assets	(4,300.21)	(271.39)
(Decrease)/Increase in Other non Current Liabilities	7.26	174.36
Changes in non current assets and liabilities		
<b>Cash generated from operations</b>	<b>771.49</b>	<b>(956.39)</b>
- Income taxes paid	-	85.16
<b>Net Cash flow before extraordinary items</b>	<b>771.49</b>	<b>(871.23)</b>
-Extraordinary & Prior period items	-	-
<b>NET CASH FROM OPERATING ACTIVITIES</b>	<b>771.49</b>	<b>(871.23)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES:</b>		
Particulars	31.03.2022	31.03.2021
<b>B.CASH FLOW FROM INVESTING ACTIVITIES:</b>		



Payments to acquire financial assets	(373.44)	(785.14)
Proceeds on sale of financial assets	-	-
Interest received	16.24	4.62
Royalties and other investment income received	-	-
Dividends received from associates	-	-
Other dividends received	-	-
Amounts advanced to related parties	-	-
Repayments by related parties	-	-
Payments for property, plant and equipment	-	-
Proceeds from disposal of property, plant and equipment	-	-
Payments for investment property	-	-
Proceeds from disposal of investment property	-	-
Payments for intangible assets	-	-
Net cash outflow on acquisition of subsidiaries	-	-
Net cash inflow on disposal of subsidiary	-	-
Net cash inflow on disposal of associate	-	-
<b>NET CASH FROM INVESTING ACTIVITIES</b>	<b>(357.21)</b>	<b>(780.51)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
<b>Particulars</b>	<b>31.03.2022</b>	<b>31.03.2021</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from issue of equity instruments of the Company	-	880.90
Proceeds from issue of convertible notes	-	-
Payment for share issue costs	-	-
Payment for buy-back of shares	-	-
Payment for share buy-back costs	-	-
Proceeds from issue of redeemable preference shares	-	-
Proceeds from issue of perpetual notes	-	-
Payment for debt issue costs	-	-
Proceeds from borrowings	-	-
(Repayment)/ Proceeds of borrowings	1,404.08	1,247.28
Proceeds from government loans	-	-
Proceeds on disposal of partial interest in a subsidiary that does not	-	-
Dividends paid on redeemable cumulative preference shares	-	-
Dividends paid to owners of the Company	-	-
Interest paid	(216.84)	(266.65)
Long Term Provisions	-	-
<b>NET CASH FROM FINANCING ACTIVITIES</b>	<b>1,187.24</b>	<b>1,861.53</b>
<b>NET INCREASE IN CASH &amp; CASH EQUIVALENTS</b>	<b>1,601.52</b>	<b>209.79</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>210.17</b>	<b>0.38</b>
Effects of exchange rate changes on the balance of cash held in foreign currencies	-	-
<b>Cash and cash equivalents at the end of the year as on</b>	<b>1,811.69</b>	<b>210.17</b>
Reconciliation of cash and cash equivalents as per the cash flow Statement	-	-
Cash and cash equivalents	1,811.69	210.17
<b>Balance as per statement of cash flows</b>	<b>18,11,69,052</b>	<b>2,10,16,979</b>





Name of the Company - <b>VINEET LABORATORIES LIMITED</b>	
<b>CIN:L24304TG2016PLC112888</b>	
<b>Hyderabad, Telangana-500074, India.</b>	
NOTES:	
1	In pursuance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been prepared and reviewed by the Statutory Auditors of Company. The same were recommended by the Audit Committee and subsequently approved by Board of Directors of Company at this meeting held on May 28, 2022.
2	The company adopted the Indian Accounting standards (Ind AS) and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. The Ind-AS Compliant Standalone Financial results for the corresponding quarter and Year ended 31.03.2022 have been stated in terms of SEBI Circular dated July, 05, 2016.
3	The results are also available on the website of the Company <a href="http://www.vineetlabs.co.in">www.vineetlabs.co.in</a>
4	The Company is engaged in only one operating segment i.e., API Intermediates. Since, there are no separate
5	As per the Hon'ble NCLT Dated 24.12.2020, the Unit-II of Ortin Laboratories Limited was demerged and the demerged unit was merged with M/s. Vineet Laboratories Limited, with effect from the appointed date i.e., 01.04.2020.
6	The Code on Social Security, 2020 relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not yet been notified. The Company will assess the impact of the Code when it comes into effect and will record only related Impact in the period the Code becomes effective.
7	The financial information pertaining to prior period have been re-grouped /re-classified wherever necessary to confirm with the classification required in order to comply with the requirements of the amended Schedule III of the Companies Act, 2013, which was effective from April 01, 2021.



Gaddam Venkata Ramana

Managing Director

DIN:-00031873

May 28, 2022

To  
The General Manager  
Department of Corporate Services  
**BSE Limited**  
P.J. Towers, Dalal Street,  
Mumbai-400001  
**Scrip Code – 543298**

To  
The Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No – C/1,  
G Block, Bandra Kurla Complex  
Bandra (East), Mumbai -400 051  
**Scrip Code - VINEETLAB**

Dear Sir/Ma'am,

**Sub: Declaration in respect of audit report with unmodified opinion**  
**Ref: Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

As required under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that the Statutory Auditors of the Company - MM Reddy & Co, Chartered Accountants, Hyderabad (Firm Registration No. 0103718) have issued their Audit Report with unmodified opinion on the Standalone Financial Results of the Company for the financial year ended on 31st March 2022.

Kindly take this information on records.

Regards,

For Vineet Laboratories Limited



Gaddam Venkata Ramana  
Managing Director  
DIN: 00031873



**Admin. Office:** 5-5-160, Malleswari Nilayam, Opp. Vishnu Theatre, Chintalkunta, LB Nagar, Hyderabad-500 074.

**Regd. Office:** Sy.No. 11/A3, Eshwaramma Nilayam, Saheb Nagar Kurudu Vill, Chintalkunta, LB Nagar, Hyderabad-500 074.

**Factory:** Sy.No. 300, Malkapur(V), Choutuppal(M), Yadadri-Bhuvanagiri(D), Telangana State, India-508 252.

E-mail: [info@vineetlabs.co.in](mailto:info@vineetlabs.co.in), Website: [www.vineetlabs.co.in](http://www.vineetlabs.co.in), Phone: +91-40-24128833,

CIN No. : U24304TG2016PLC112888

GST No. : 36AAFCV6694P1ZA